[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"exosome-multiomics\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:exosome-multiomics":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":20,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100581952","early-evaluation-of-exosome-multiomics-and-clinical-prognosis-in-patients-with-sudden-death-100581952",false,"NCT06856993","Early Evaluation of Exosome Multiomics and Clinical Prognosis in Patients With Sudden Death","Inclusion Criteria:\n\n* The death event happens suddenly.\n* Age ≥ 18 years\n* The patient had obvious clinical symptoms 24 hours before treatment\n* Life expectancy exceeds 3 days\n* Proxy of patients signs the informed consent form\n* Comply with ACS diagnostic indicators recommended by ACC \u002F AHA guidelines in 2016\n\nExclusion Criteria:\n\n* Death caused by accident, such as trauma, poisoning, etc.\n* Death from accidental or intentional overdose\n* Death from asphyxia\n* Death is caused by chronic disease or terminal illness\n* The patient died naturally\n* Has participated in other clinical studies\n* Immediate family members give up continuing treatment","ALL","18 Years",{"count":18,"type":19},300,"ESTIMATED","3 Months","OBSERVATIONAL","Acute coronary syndrome (ACS) is one of the main causes of death. Worldwide, tens of millions of patients are hospitalized for coronary heart disease and ACS every year. ACS may show acute myocardial infarction, unstable angina pectoris, and even induce early arrhythmia, leading to sudden death. Sudden cardiac death (SCD) has a strong correlation with ACS. Data from clinical and autopsy studies and death certificates show that 62-85% of patients with out of hospital SCD have a history of ACS, 10% have other cardiac structural abnormalities, and 5% have no cardiac structural abnormalities. An SCD surveillance study from Ireland concluded that most cases occurred in families, and the successful recovery of SCD was mainly related to ventricular fibrillation with arrhythmia. At present, there are few reports on the clinical and prognosis of ACS in China, and there is no guideline or consensus on the prevention and treatment of ACS patients. Known domestic research results show that the proportion of male, overweight \u002F obese, smokers in young ACS patients is higher than that in the elderly group, while the proportion of patients with hypertension, diabetes and cerebrovascular diseases is less than that of the elderly group. The levels of TC, TG, LDL-C and UA and the proportion of low HDL-C in young ACS patients were higher than those in elderly patients; The diagnosis of STEMI was the highest in the young ACS group, while the diagnosis of unstable angina pectoris was the most common in the elderly ACS group. The clinical manifestations of ACS vary greatly. 3% \\~ 5% of patients who exclude ACS only through myocardial markers, clinical blood transfusion and ECG still have myocardial infarction (MI). For the emergency department, early prediction of the risk of SCD in ACS patients and timely and accurate screening of high-risk patients are very important.",[24,25,26],"Sudden Cardiac Death","Exosome Multiomics","Clinical Prognosis","RECRUITING","2026-04-06",{"date":30,"type":31},"2026-04-08","ACTUAL",{"date":33,"type":31},"2021-12-22",{"date":35,"type":19},"2027-12-31",{"name":37,"class":38},"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":48,"minAge":16,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":56,"conditions":57,"keywords":62,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":39},"100607040","phase-1-msc-exosome-therapy-for-post-preeclampsia-endothelial-dysfunction-100607040","NCT07183384","MSC Exosome Therapy for Post-Preeclampsia Endothelial Dysfunction","The Effectiveness of Mesenchymal Stem Cell-Derived Exosome Therapy in Improving Endothelial Dysfunction in Postpartum Mothers With a History of Preeclampsia","EXITPE","Inclusion Criteria:\n\n* Postpartum\n* Confirmed diagnosis of preeclampsia in the last pregnancy\n* Postpartum period of first week and second week\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* History of chronic hypertension prior to pregnancy\n* Major cardiovascular disease history\n* Active systemic infection\n* Endothelial Injury history\n* Active smoking status including vape, alcohol, drug addiction.","FEMALE","50 Years",{"count":51,"type":19},80,"INTERVENTIONAL",[54,55],"PHASE1","PHASE2","\\---\n\nWhy Is This Study Being Done?\n\nWomen who have preeclampsia during pregnancy face a much higher risk of heart disease later in life. Preeclampsia is a serious pregnancy condition that causes high blood pressure and damages blood vessels. Even after the baby is born, the blood vessels do not fully heal on their own, which can lead to heart problems\u002Fcardiovascular years later.\n\nThis study tests whether a new treatment called exosomes can help repair damaged blood vessels in women who had preeclampsia. Exosomes are tiny particles that come from stem cells and contain healing substances that may help blood vessels work better.\n\n\\---\n\nWhat Will Happen in This Study?\n\nThis study will include 80 women who recently gave birth and had preeclampsia during their pregnancy. Half of the women will receive the exosome treatment through an IV, and half will receive a placebo (a substance with no active treatment).\n\n\\---\n\nWhat Will Participants Need to Do?\n\nParticipants will:\n\n* Have blood tests and other health checks\n* Receive one treatment through an IV\n* Return for follow-up visits at 1 week after treatment\n* Have tests to check how well their blood vessels are working\n\nWho Can Join This Study?\n\nWomen who:\n\n* Recently gave birth (within 1-2 weeks)\n* Had preeclampsia during their last pregnancy\n* Are healthy enough to participate\n* Can give permission to join the study\n\nWhat Are the Possible Benefits and Risks?\n\nThe treatment may help repair blood vessel damage and reduce the risk of future heart disease. The exosome treatment appears to be safe based on other studies, but like any medical treatment, there may be side effects.\n\n\\---\n\nHow Long Will the Study Last?\n\nThe main treatment happens during one visit, with follow-up visits for 1 week to check on participants' health and see if the treatment is working.\n\nThis research may lead to new ways to protect women's heart health after pregnancy complications.",[58,59,60,25,61],"Preeclampsia","Postpartum","Endothelial Injury","Cell Therapy",[58,59,63,64,61],"Stem Cell","Exosome","2025-09-12",{"date":67,"type":31},"2025-09-19",{"date":69,"type":31},"2024-07-01",{"date":71,"type":19},"2026-09-01",{"name":73,"class":38},"Universitas Padjadjaran"]